GERM LINEAGE DERIVED FEEDER CELLS AND METHODS THEREOF

• US 20100047906A1
• Filed: 06/19/2009
• Published: 02/25/2010
• Est. Priority Date: 12/19/2006
• Status: Abandoned Application

• Current Assignee: Stempeutics Research Private Limited
• Original Assignee: Stempeutics Research Private Limited
• Inventors: Totey, Satish, Saxena, Shobhit, Kulkarni, Kumar Uday
• Application Number:
  US12/488,150
• Publication Number:
  US 20100047906A1
• Time in Patent Office: Days
• US Class Current: 435/366
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2500/90 Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 2501/105 Insulin-like growth factors [IGF]
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/117 Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
• CPC Class Codes: C12N 2501/12 Hepatocyte growth factor [HGF]
• CPC Class Codes: C12N 2501/125 Stem cell factor [SCF], c-kit ligand [KL]
• CPC Class Codes: C12N 2501/13 Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
• CPC Class Codes: C12N 2501/135 Platelet-derived growth factor [PDGF]
• CPC Class Codes: C12N 2501/15 Transforming growth factor beta (TGF-β)
• CPC Class Codes: C12N 2501/155 Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2501/16 Activin; Inhibin; Mullerian inhibiting substance
• CPC Class Codes: C12N 2502/02 embryonic cells
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696

Abstract

The present disclosure relates to human germ layer derived feeder cells (GLDF cells) and method of generation thereof. Further, it relates to a method for culturing and propagating human embryonic stem cells (hESCs) in a substantially undifferentiated state for several passages on the human GLDF cells. In particular, the present disclosure relates to human GLDF cells which are capable of supporting proliferation of hESCs in a substantially undifferentiated and pluripotent state for several passages.

Claims

1. A method of generating human germ lineage derived feeder cells (GLDF cells), said method comprising:

a. culturing human embryonic stem cells (hESC) on growth medium to obtain germ lineage cells;

b. culturing said germ lineage cells on GLDF medium to obtain fibroblast like cells; and

c. treating said fibroblast like cells to generate human GLDF cells.

2. The method as claimed in claim 1, wherein the growth medium comprises KO-DMEM, serum replacement, about 1 mM glutamine, about 1% nonessential amino acids (NEAA), about 0.1 mM β

-mercaptoethanol, and an antibiotic.

3. The method as claimed in claim 1, wherein the GLDF medium comprises of KO-DMEM, growth factors, serum supplement or a combination thereof.

4. The method as claimed in claim 3, wherein the growth factors are selected from a group consisting of transforming growth factor-β

-1 (TGF-β

-1), epidermal growth factor (EGF), brain derived neurotrophic factor (BDNF), platelet derived growth factor (PDGF), Insulin, selenite, transferrin, Activin-A, Activin-B, Acidic FGF, human Insulin growth factor (IGF), Keratenocyte growth factor (KGF), stem cell factor (SCF), bone morphogenic protein (BMP4), hepatocyte growth factor (HGF), nerve growth factor (NGF) and a combination thereof.

5. The method as claimed in claim 1, wherein the GLDF medium comprises KO-DMEM, about 10% KO-Serum, about 1×

Insulin-transferrin-selinium, about 1×

10<sup>−

8</sup> dexamethasone, about 1% glutamine, antibiotic, about 10 ng/ml epidermal growth factor (EGF) or a combination thereof.

6. The method as claimed in claim 4, wherein the TGF-β

-1 is provided at a concentration of about 1-20 η

g/ml.

7. The method as claimed in claim 4, wherein the EGF is provided at the concentration of about 1-20 ng/ml.

8. The method as claimed in claim 4, wherein the activin A is provided at the concentration of about 5-100 ng/ml.

9. The method as claimed in claim 4, wherein the activin B is provided at the concentration of about 5-100 ng/ml.

10. The method as claimed in claim 4, wherein the acidic FGF is provided at the concentration of about 1-20 ng/ml.

11. The method as claimed in claim 4, wherein the BDNF is provided at the concentration of about 1-20 ng/ml.

12. The method as claimed in claim 4, wherein the PDGF is provided at the concentration of about 1-20 η

g/ml.

13. The method as claimed in claim 4, wherein the IGF is provided at the concentration of about 2-20 ng/ml.

14. The method as claimed in claim 4, wherein the KGF is provided at the concentration of about 10-50 ng/ml.

15. The method as claimed in claim 4, wherein the SCF is provided at the concentration of about 5-20 ng/ml.

16. The method as claimed in claim 4, wherein the BMP4 is provided at the concentration of 5-20 ng/ml.

17. The method as claimed in claim 4, wherein the HGF is provided at the concentration of about 10-20 ng/ml.

18. The method as claimed in claim 4, wherein the NGF is provided at the concentration of about 20-100 ng/ml.

19. The method as claimed in claim 1, wherein said fibroblast like cells were treated with mitomycin.

20. Human GLDF cells for culturing human embryonic stem cells (hESCs), wherein the GLDF cells are generated by the method as claimed in claim 1.

21. The human GLDF cells as claimed in claim 20, wherein the cells are fibroblast-like cells.

22. The human GLDF cells as claimed in claim 20, wherein the cells are negative for the expression of pluripotent markers selected from the group consisting of OCT-4, NANOG, REX-1, TDGF, SOX-2, and TERT.

23. The human GLDF cells as claimed in claim 20, wherein the cells are positive for the fibroblast phenotypic marker P4HB and mesenchymal stem cell marker Vimentin.

24. The human GLDF cells as claimed in claim 20, wherein cells are positive for mesenchymal stem cell markers CD73, CD105, CD90, CD44.

25. The human GLDF cells as claimed in claim 20, wherein the cells are positive for the expression of differentiation markers selected from the group of NCAM, β

-III tubulin, GATA2, Hand 1, BMP4, Vimentin, CK18, Nestin, NF heavy chain, GFAP, and CK19.